The Omnipod 5 System consists of a tubeless wearable Pod, the Omnipod 5 mobile app, and the Dexcom G6 Continuous Glucose Monitoring System. The Food and Drug Administration (FDA) has cleared the ...

Diabetes is a chronic health condition affecting blood glucose levels. In some cases, it requires constant management in the form of monitoring blood glucose levels and administering insulin.

Insulin pump-maker Insulet has scored FDA 510(k) clearance for its Omnipod 5 Automated Insulin Delivery System for people ages 6 and up with Type 1 diabetes. The pump integrates with the Dexcom G6 ...

Insulet (($PODD)) announced an update on their ongoing clinical study. Insulet Corporation is conducting a clinical study titled ‘Safety and ...

Insulet Corporation PODD recently received CE mark approval under the European Medical Device Regulation for the added compatibility of the Abbott Laboratories’ ABT FreeStyle Libre 2 Plus sensor with ...

Insulet has announced that its Omnipod 5 Automated Insulin Delivery System has been cleared by the US Food and Drug Administration (FDA) for the indication of type 2 diabetes. The company says that ...

Patients with type 1 diabetes (T1D) who used the Omnipod 5 Automated Insulin Delivery (AID) System saw significant improvements in psychosocial outcomes, including diabetes distress and hypoglycemic ...

The clearance was based on data from a single-arm multicenter clinical trial that evaluated the Omnipod 5 system in 80 children aged 2 to 5.9 years with type 1 diabetes. The Food and Drug ...

Insulet (($PODD)) announced an update on their ongoing clinical study. Insulet Corporation has announced a new clinical study titled ‘Omnipod 5 – ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...